Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 7959-7978

  Radia, AL Madhagi ^a   Yaser, AL Madhagi ^b   Ma, Xiaoqian ^a   Zhang, Juan ^a   Yang, Cejun ^a   Dong, Qiong ^a   Rong, Pengfei ^a   Ye, Bin ^a   Liu, Sheng ^a   Wang, Wei ^a  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Breast cancer; Proliferation; RAGE; siRNA

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLIN D1; CYCLINE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CCND1 PROTEIN, HUMAN; DNA; IMMUNOGLOBULIN RECEPTOR; RELA PROTEIN, HUMAN; RNA;

ADVANCED GLYCATION END PRODUCT RECEPTOR GENE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CYCLIND1 GENE; DNA SYNTHESIS; DOWN REGULATION; FLOW CYTOMETRY; GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; NF KAPPAB P65 GENE; PCNA GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; CELL SURVIVAL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DNA, NEOPLASM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84876320541     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14047959     Document Type: Article

References (61)

1. Poellinger, A. Near-infrared imaging of breast cancer using optical contrast agents. J. Biophotonics 2012, 5, 815-826.
2. Smolarek, A.K.; Suh, N. Chemopreventive activity of vitamin E in breast cancer. A focus on ã- and ä-Tocopherol. Nutrients 2011, 3, 962-986.
3. Beckmann, M.W.; Niederacher, D.; Schnurch, H.G.; Gusterson, B.A.; Bender, H.G. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J. Mol. Med. 1997, 75, 429-439.
4. Lerebours, F.; Lidereau, R. Molecular alterations in sporadic breast cancer. Crit. Rev. Oncol. Hematol. 2002, 44, 121-141.
5. Balmain, A.; Gray, J.; Ponder, B. The genetics and genomics of cancer. Nat. Genet. 2003, 33, 238- 244.
6. Cynthia, O.; Paschal, W.; Debu, T. Oncogenes and tumor suppressor genes in breast cancer: Potential diagnostic and therapeutic applications. Oncologist 2004, 9, 361-377.
7. DeNardo, D.G.; Coussens, L.M. Inflammation and breast cancer: Balancing immune response-Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9, 212.
8. Blows, F.M.; Driver, K.E.; Schmidt, M.K.; Broeks, A.; van Leeuwen, F.E.; Wesseling, J.; Cheang, M.C.; Gelmon, K.; Nielsen, T.O.; Blomqvist, C.; et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival. A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010, 7, e1000279.
9. Badve, S.; Dabbs, D.J.; Schnitt, S.J.; Baehner, F.L.; Decker, T.; Eusebi, V.; Fox, S.B.; Ichihara, S.; Jacquemier, J.; Lakhani, S.R.; et al. Basal-like and triple-negative breast cancers. A critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011, 24, 157-167.
10. Rakha, E.A.; Ellis, I.O.; Reis-Filho, J.S. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod. Pathol. 2008, 21, 1060-1061.
11. Subhawong, A.P.; Subhawong, T.; Nassar, H.; Kouprina, N.; Begum, S.; Vang, R.H.; Westra, W.; Argani, P. Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am. J. Surg. Pathol. 2009, 33, 163-175.
12. Reis-Filho, J.S.; Tutt, A.N. Triple negative tumours: A critical review. Histopathology 2008, 52, 108-118.
13. Nielsen, T.O.; Hsu, F.D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; et al. Immunohistochemical and clinical characterization of the basal like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10, 5367-5374.
14. Abd El-Rehim, D.M.; Pinder, S.E.; Paish, C.E.; Bell, J.; Blamey, R.W.; Robertson, J.F.; Nicholson, R.I.; Ellis, I.O. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004, 203, 661-671.
15. Fan, C.; Oh, D.S.; Wessels, L.; Weigelt, B.; Nuyten, D.S.; Nobel, A.B.; van't Veer, L.J.; Perou, C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 2006, 355, 560-569.
16. Peppercorn, J.; Perou, C.M.; Carey, L.A. Molecular subt-ypes in breast cancer evaluation and management: Divide and conquer. Cancer Invest. 2008, 26, 1-10.
17. Tan, D.S.; Marchío, C.; Jones, R.L.; Savage, K.; Smith, I.E.; Dowsett, M.; Reis-Filho, J.S. Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 2008, 111, 27-44.
18. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363, 1938-1948.
19. Liedtke, C.; Mazouni, C.; Hess, K.R.; André, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275-1281.
20. Owens, M.A.; Horten, B.C.; da Silva, M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004, 5, 63-69.
21. Baselga, J.; Swain, S.M. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9, 463-475.
22. Srikrishna, G.; Huttunen, H.J.; Johansson, L.; Weigle, B.; Yamaguchi, Y.; Rauvala, H.; Freeze, H.H. N-glycans on the receptor for advanced glycan end products influence amphoterin binding and neurite out growth. J. Neurochem. 2002, 80, 998-1008.
23. Al-Madhagi, Y.; Yan, H.; Rong-Rong, Z.; Guan-Sheng, H.; Mei-Fang, X.; Zhe-Bing, H.; Chao-Jun, D.; Wei, T.; Dao-Lin, T.; Xue-Gong, F. The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int. J. Mol. Sci. 2012, 13, 5982-5997.
24. Logsdon, C.D.; Fuentes, M.K.; Huang, E.H.; Arumugam, T. RAGE and RAGE ligands in cancer. Curr. Mol. Med. 2007, 7, 777-789.
25. Bierhaus, A.; Nawroth, P.P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009, 52, 2251-2263.
26. Kojro, E.; Postina, R. Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease. J. Alzheimers. Dis. 2009, 16, 865-878.
27. Brett, J.; Schmidt, A.M.; Yan, S.D.; Zou, Y.S.; Weidman, E.; Pinsky, D.; Nowygrod, R.; Neeper, M.; Przysiecki, C.; Shaw, A. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 1993, 143, 1699-1712.
28. Clynes, R.; Moser, B.; Yan, S.F.; Ramasamy, R.; Herold, K.; Schmidt, A.M. Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response. Curr. Mol. Med. 2007, 7, 743-751.
29. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J. Mol. Med. 2009, 87, 235-247.
30. Chen, X.; Walker, D.G.; Schmidt, A.M.; Arancio, O.; Lue, L.F.; Yan, S.D. RAGE: A potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr. Mol. Med. 2007, 7, 735-742.
31. Liguo, L.; Kaihua, Z.; Zhongkai, S.; Guozhong, W.; Guodong, D. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J. Cancer Res. Clin. Oncol. 2012, 138, 11-22.
32. Kiyokazu, H.; Shinichi, U.; Kazuhiro, A.; Fumitake, K.; Masahiko, S.; Ikuro, M.; Masahiro, H.; Shoji, N.; Takashi, A. Novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Ann. Surg. Oncol. 2008, 15, 923-933.
33. Yamamoto, Y.; Kato, I.; Doi, T.; Yonekura, H.; Ohashi, S.; Takeuchi, M.; Watanabe, T.; Yamagishi, S.; Sakurai, S.; Takasawa, S.; et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 2001, 108, 261-268.
34. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J.M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285, 248-251.
35. Liliensiek, B.; Weigand, M.A.; Bierhaus, A.; Nicklas, W.; Kasper, M.; Hofer, S.; Plachky, J.; Gröne, H.J.; Kurschus, F.C.; Schmidt, A.M.;et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 2004, 113, 1641-1650.
36. Hudson, B.I.; Kalea, A.Z.; Arriero, M.D.; Harja, E.; Boulanger, E.; D'Agati, V.; Schmidt, A.M. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 2008, 283, 34457-34468.
37. Demling, N.; Ehrhardt, C.; Kasper, M.; Laue, M.; Knels, L.; Rieber, E. Promotion of cell adherence and spreading: A novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells.Cell Tissue Res. 2006, 323, 475-488.
38. Ramasamy, R.; Yan, S.F.; Schmidt, A.M. Arguing for the motion. Yes, RAGE is a receptor for advanced glycation end products. Mol. Nutr. Food Res. 2007, 51, 1111-1115.
39. Brezniceanu, M.L.; Volp, K.; Bosser, S.; Solbach, C.; Lichter, P.; Joos, S.; Zornig, M. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J. 2003, 17, 1295-1297.
40. Flohr, A.M.; Rogalla, P.; Meiboom, M.; Borrmann, L.; Krohn, M.; Thode-Halle, B.; Bullerdiek, J. Variation of HMGB1 expression in breast cancer. Anticancer Res. 2001, 21, 3881-3885.
41. Lum, H.K.; Lee, K.L. The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron. Biochim. Biophys. Acta 2001, 1520, 79-84.
42. Hsieh, H.L.; Schafer, B.W.; Sasaki, N.; Heizmann, C.W. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun. 2003, 307, 375-381.
43. Taguchi, A.; Blood, D.C.; del Toro, G.; Canet, A.; Lee, D.C.; Qu, W.; Tanji, N.; Lu, Y.; Lalla, E.; Fu, C.; et al. Blockade of RAGE amphoterin signaling suppresses tumor growth and metastases. Nature 2000, 405, 354-360.
44. Kuniyasu, H.; Oue, N.; Wakikawa, A.; Shigieshi, H.; Matsutani, N.; Kuraoka, K.; Ito, R.; Yokozaki, H.; Yasui, W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 2002, 196, 163-170.
45. Kuniyasu, H.; Chihara, Y.; Kondo, H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer 2003, 104, 722-727.
46. Kuniyasu, H.; Chihara, Y.; Takahashi, T. Co-Expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 2003, 10, 445-448.
47. Hirata, K.; Takada, M.; Suzuki, Y.; Kuroda, Y. Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepatogastroenterology 2003, 50, 1205-1207.
48. Takada, M.; Koizumi, T.; Toyama, H.; Suzuki, Y.; Kuroda, Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001, 48, 1577-1578.
49. Ishiguro, H.; Nakaigawa, N.; Miyoshi, Y.; Fujinami, K.; Kubota, Y.; Uemura, H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64, 92-100.
50. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu. Rev. Immunol. 2000, 18, 621-663.
51. Cheng, Q.; Cant, C.A.; Moll, T.; Hofer-Warbinek, R.; Wagner, E.; Birnstiel, M.L.; Bach, F.H.; de Martin, R. NK-kappa B subunit-specific regulation of the I kappa B alpha promoter. J. Biol. Chem. 1994, 269, 13551-13557.
52. Yeh, C.H.; Sturgis, L.; Haidacher, J.; Zhang, X.N.; Sherwood, S.J.; Bjercke, R.J.; Juhasz, O.; Crow, M.T.; Tilton, R.G.; Denner, L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE mediated nuclear factor-k{cyrillic}B transcriptional activation and cytokine secretion. Diabetes 2001, 50, 1495-1504.
53. Huttunen, H.J.; Fages, C.; Rauvala, H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274, 19919-19924.
54. Gilmore, T.D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene 2006, 25, 6680-6684.
55. Brasier, A.R. The NF-κB regulatory network. Cardiovasc. Toxicol. 2006, 6, 111-130.
56. Perkins, N.D. Integrating cell-signalling pathways with NF-B and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8, 49-62.
57. Tian, B.; Brasier, A.R. Identification of a nuclear factor NF-κB -dependent gene network. Recent Prog. Horm. Res. 2003, 58, 95-130.
58. Jones, R.L.; Rojo, F.G.; A'Hern, R.; Villena, N.; Corominas, J.; Servitja, S.; Corominas, J.M.; Servitja, S.; Smith, I.E.; Rovira, A.; et al.Nuclear NF-κB p65 expression and response to neoadjuvant chemotherapy in breast cancer. J. Clin. Pathol. 2011, 64, 130-135.
59. Gramantieri, L.; Trere, D.; Chieco, P.; Lacchini, M.; Giovannini, C.; Piscaglia, F.; Cavallari, A.; Bolondi, L. In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. J Hepatol. 2003, 39, 997-1003
60. Daolin, T.; Rui, K.; Herbert, J.Z.; Michael, T.L. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 2010, 1799, 131-140.
61. Hinz, M.; Krappmann, D.; Eichten, A.; Heder, A.; Scheidereit, C.; Strauss, M. NF-κB function in growth control, Regulation of cyclin D1 expression and G0/G1-to-S-Phase transition. Mol. Cell Biol. 1999, 19, 2690-2698.